T(11;19) Q23P133 MLL-ENL PCR Qualitative Test
Comprehensive Introduction to MLL-ENL Genetic Testing
The T(11;19) Q23P133 MLL-ENL PCR Qualitative Test represents a cutting-edge advancement in molecular diagnostics for leukemia detection and management. This specialized genetic test focuses on identifying the specific chromosomal translocation between chromosomes 11 and 19, known as t(11;19)(q23;p13.3), which results in the formation of the MLL-ENL fusion gene. This genetic abnormality is clinically significant as it disrupts normal cellular regulation and contributes to the development of various forms of acute leukemia.
At General Genetics Corporation, we understand the critical importance of accurate genetic testing in leukemia diagnosis and treatment planning. Our state-of-the-art molecular diagnostics laboratory employs real-time PCR technology to deliver precise, reliable results that healthcare providers can trust for making informed clinical decisions.
What This Test Measures and Detects
The T(11;19) Q23P133 MLL-ENL PCR Qualitative Test specifically targets and identifies:
- The presence of t(11;19)(q23;p13.3) chromosomal translocation
- Formation of the MLL-ENL fusion gene
- Genetic abnormalities associated with acute myeloid leukemia (AML)
- Specific leukemia subtypes linked to MLL gene rearrangements
- Minimal residual disease monitoring capabilities
This test utilizes highly sensitive real-time PCR methodology to detect even low levels of the fusion gene, making it valuable for both initial diagnosis and ongoing monitoring of treatment response.
Who Should Consider This Test
This specialized genetic test is recommended for individuals presenting with:
- Suspected or newly diagnosed acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL) with unusual presentation
- Patients with treatment-resistant leukemia
- Individuals requiring prognostic assessment for leukemia
- Patients being evaluated for targeted therapy options
- Those with family history of hematological malignancies
- Individuals with abnormal blood counts and unexplained symptoms
Common Symptoms and Clinical Indications
- Unexplained fatigue and weakness
- Frequent infections and fever
- Easy bruising or bleeding
- Bone pain or tenderness
- Enlarged lymph nodes, liver, or spleen
- Unexplained weight loss
- Night sweats
Benefits of Taking the T(11;19) MLL-ENL Test
Choosing this advanced genetic test provides numerous clinical advantages:
- Accurate Diagnosis: Precise identification of specific leukemia subtypes
- Prognostic Information: Helps predict disease course and treatment response
- Treatment Guidance: Informs selection of appropriate therapeutic approaches
- Minimal Residual Disease Monitoring: Enables detection of low-level disease after treatment
- Early Detection: Identifies genetic abnormalities before full disease manifestation
- Personalized Medicine: Supports development of targeted treatment strategies
Understanding Your Test Results
Your test results will be carefully interpreted by our expert molecular pathologists and provided with comprehensive clinical context:
Positive Result Interpretation
A positive result indicates the presence of the t(11;19) translocation and MLL-ENL fusion gene. This finding:
- Confirms the diagnosis of leukemia associated with this specific genetic abnormality
- Provides important prognostic information for treatment planning
- May influence the selection of specific chemotherapy regimens
- Can be used for monitoring treatment response over time
Negative Result Interpretation
A negative result indicates the absence of the specific MLL-ENL fusion gene:
- Helps rule out leukemia subtypes associated with this translocation
- May suggest alternative genetic abnormalities or leukemia subtypes
- Provides baseline information for future monitoring
- Does not completely rule out other forms of leukemia
Test Pricing and Availability
| Price Type | Amount (USD) |
|---|---|
| Discount Price | $126 |
| Regular Price | $162 |
Test Specifications
- Turnaround Time: Samples accepted Monday/Thursday by 11 AM; Reports delivered Wednesday/Saturday
- Sample Type: 3 mL (2 mL minimum) whole blood or bone marrow in Lavender Top (EDTA) tube
- Shipping Instructions: Ship refrigerated. DO NOT FREEZE
- Specialty: Oncologist
- Department: Molecular Diagnostics
- Method: Real Time PCR
- Disease Focus: Leukemia
Nationwide Accessibility
General Genetics Corporation has diagnostic centers conveniently located throughout the United States, serving patients in all major metropolitan areas including:
- New York City and surrounding areas
- Los Angeles and Southern California
- Chicago and Midwest regions
- Houston and Texas locations
- Miami and Florida centers
- Seattle and Pacific Northwest facilities
- And many more locations nationwide
Take Action for Your Health
Don’t wait to get the critical genetic information you need for proper leukemia diagnosis and management. Our experienced team is ready to provide you with the highest quality molecular diagnostic services.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your T(11;19) Q23P133 MLL-ENL PCR Qualitative Test. Our knowledgeable staff will guide you through the testing process, answer your questions, and ensure you receive the comprehensive care you deserve.
Early and accurate genetic testing can make a significant difference in leukemia treatment outcomes. Trust General Genetics Corporation for reliable, advanced molecular diagnostics that put your health first.
